Frequently Asked Questions:
- What is the VALUE study?
VALUE is a prospective, observational, multicountry study comparing real-world drug survival with risankizumab and with other biologics in adults with moderate to severe psoriasis.
- What did the final 3-year VALUE analysis show?
Among matched patients with psoriasis and psoriatic arthritis, 18.2% of risankizumab recipients changed therapy by month 37, compared with 33.1% of those on other biologics.
- How did risankizumab compare with IL-17 inhibitors?
Drug changes occurred in 18.2% of patients receiving risankizumab and 25.5% of those receiving IL-17 inhibitors. The difference was not statistically significant (P = .268).
Patients with plaque psoriasis and comorbid psoriatic arthritis who started risankizumab (Skyrizi) were less likely to stop or switch therapy over 37 months than those who started other biologics. The findings come from the final results of the VALUE study, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada.¹
The difference was largest compared with tumor necrosis factor inhibitors (TNFi), while differences compared with interleukin (IL)-17 inhibitors weren’t statistically significant.¹ The results build on an interim analysis presented at the 2025 Fall Clinical meeting, which showed higher drug survival with risankizumab at 25 months in the same population.²
About one-third of patients with psoriasis develop psoriatic arthritis, and this combination requires durable therapy to control both skin and joint disease over time.¹ Drug survival, or how long those being treated stay on a given biologic, is known to be a real-world marker of long-term treatment success.
How Was the VALUE Study Designed?
VALUE (NCT03982394) is a multicountry, prospective, observational study. It enrolled adults with moderate to severe psoriasis prescribed either risankizumab, an IL-23 p19 inhibitor, or another biologic according to local labeling, in a 2:1 ratio.¹ This post hoc analysis focused on 462 patients with psoriatic arthritis diagnosed by a rheumatologist.
To balance baseline characteristics, investigators used 1:1 propensity score matching, with exact matching on prior biologic use, which produced 121 patients per group.¹ The groups were comparable at baseline:
- Mean age: 51.0 years with risankizumab and 50.4 years with other biologics
- Mean Psoriasis Area and Severity Index score: 14.0 and 14.1
- Mean affected body surface area: 21.7% and 20.2%
- Biologic-naive: 56.2% in each group¹
Investigators defined drug survival as continued use of the biologic received at enrollment. A drug change meant stopping the biologic or switching to another.¹ The reported P values are nominal.
How Did Risankizumab Drug Survival Compare With Other Biologics?
By month 37, 18.2% (22/121) of risankizumab recipients had a drug change, compared with 33.1% (40/121) of patients receiving other biologics (P < .01).¹ Kaplan-Meier estimates of the probability of a drug change were shown to be 0.20 (95% CI, 0.14-0.30) with those in the risankizumab arm and 0.35 (95% CI, 0.27-0.46) with other biologics (log-rank P < .01).
